ACCURACY OF mRNA HPV TESTS FOR DIAGNOSTIC TRIAGE OF MINOR CYTOLOGICAL CERVICAL LESIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
The main objective of this systematic review and meta-analysis is to specify the accuracy of mRNA HPV tests among women with previous minor cervical lesion cytology to detect high-grade squamous intra-epithelial lesions (CIN2+ and CIN3+), comparing to a histopathological reference standard. The secondary objective is to compare mRNA HPV tests accuracies and the DNA hrHPV test among these women. Eligible studies were identified by searching the electronic databases with medical subject headings (MeSH). Among the 2,052 studies identified, twenty primary studies were included. Two tests were mainly identified: Aptima and PreTect HPV-Proofer. Aptima, with 10 studies, had better performance, considering ASC-US and LSIL together, with a pooled sensitivity of 90.5% (95%CI: 88.1-92.6) and specificity of 55.1% (95%CI: 53.5-56.8) for CIN2+. For the ASC-US sample, Aptima had a pooled sensitivity of 90.1% (95%CI: 87.1-92.7) and specificity of 59.3% (95%CI: 57.5-61.1). mRNA HPV tests, mainly Aptima assay, can be recommended to triage women with ASC-US and LSIL, because it has higher specificity with a small loss of sensitivity than HC2; this finding is promising as a means to reduce the over-management of minor cytological abnormalities.